GlassScriptPhysician profile
Amanda Fishback Cashen
NPI 1215953534
$33,410.99
in general payments reported to CMS, 2019-2025
15 companies · $5,124 in 2025
The $5,124 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,902 · 2020: $450 · 2021: $1,809 · 2023: $7,923 · 2024: $12K · 2025: $5,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $12K · Consulting Fee: $12K · Food and Beverage: $1,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $12,491.92 |
| Consulting Fee | $11,615.00 |
| Food and Beverage | $1,143.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| F. Hoffmann-La Roche Ag | $12,019.46 | 2024 | |
| Kite Pharma, INC. | $8,285.00 | 2023-2025 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $4,813.84 | 2021-2025 | |
| Agios Pharmaceuticals, INC. | $4,701.67 | 2019 | |
| Secura Bio, INC. | $1,711.75 | 2021-2025 | Copiktra |
| Seagen INC. | $1,200.00 | 2019 | |
| Beigene, LTD. | $450.00 | 2020 | |
| Epizyme, INC. | $103.06 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $46.50 | 2023 | Imbruvica |
| Adc Therapeutics America, INC. | $40.90 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $20.43 | 2025 | Calquence |
| Abbvie INC. | $18.38 | 2024 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Cashen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.